Sysmex (FRA:0YX) Total Liabilities : €1,111 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sysmex Total Liabilities?

Sysmex's Total Liabilities for the quarter that ended in Sep. 2024 was €1,111 Mil.

Sysmex's quarterly Total Liabilities declined from Mar. 2024 (€1,142.32 Mil) to Jun. 2024 (€0.00 Mil) but then increased from Jun. 2024 (€0.00 Mil) to Sep. 2024 (€1,111.43 Mil).

Sysmex's annual Total Liabilities declined from Mar. 2022 (€1,031.11 Mil) to Mar. 2023 (€997.26 Mil) but then increased from Mar. 2023 (€997.26 Mil) to Mar. 2024 (€1,142.32 Mil).

Sysmex Total Liabilities Historical Data

The historical data trend for Sysmex's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sysmex Total Liabilities Chart

Sysmex Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Total Liabilities

Get a 7-Day Free Trial

932.54

918.10

1,031.11

997.26

1,142.32

Sysmex Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															872.78	1,020.76	1,142.32	-	1,111.43

Sysmex Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Sysmex's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	725.125	+	(286.651	+	116.798
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	13.749)
	=	1,142

Total Liabilities	=	Total Assets (A: Mar. 2024 )	-	Total Equity (A: Mar. 2024 )
	=	3800.639	-	2658.316
	=	1,142

Sysmex's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	676.932	+	(298.207	+	121.176
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	15.114)
	=	1,111

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	3895.47	-	2784.04
	=	1,111

Sysmex Total Liabilities Related Terms

Thank you for viewing the detailed overview of Sysmex's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Sysmex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sysmex Corp (FRA:0YX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SSMXY:USA SSMXF:USA 6869:Japan 0YX:Germany

Address

1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, JPN, 6510073

Website

http://www.sysmex.co.jp

Sysmex Corp manufactures and distributes in vitro diagnostic instruments, reagents, and software. The vast majority of the firm's revenue comes from selling tests for human bodily fluids to hospitals and commercial laboratories. Within this industry, the firm specializes in hematology reagents and instruments. Sysmex also sells in vitro diagnostics for applications like urinalysis and hemostasis and provides support and maintenance services for its systems. Over half of the firm's revenue is generated by sales of reagents and services, which are recurring sources of income. Sysmex primarily sells its products to customers in Japan, Europe, the Middle East, and Africa, and the Americas.

Sysmex Headlines

No Headlines